吴骁（邮箱：xwu@njucm.edu.cn），博士，副教授，硕士研究生导师。2018年博士毕业于中国药科大学药物分析专业，现任南京中医药大学医学院专任教师。

        主要从事毒性矿物药的安全性及配伍减毒机制研究，系统评价了含雄黄经典名方牛黄解毒片和安宫牛黄丸的安全性及体内重金属代谢形态，并结合肠道菌群和系统生物学等技术分析其配伍减毒分子机制，为重金属矿物药质量标准的提高和临床安全应用提供了科学依据。先后主持国家自然科学基金（No.82104523）、江苏省自然科学基金（No.BK20200843）等多项课题，相关研究成果发表学术论文20余篇，获第六届全国药物分析大会优秀论文一等奖、第七届全国药物分析大会优秀论文二等奖、第六届《药物分析杂志》优秀论文三等奖、第八届《药物分析杂志》优秀论文奖等。

        代表性研究论文

        [1] Li, J J, Gu J, Pan S J, Deng N, Khan M*, Li L Y, Wu X*, Li Y M*. Synergic effect of the combination of Isoliquiritigenin and Arsenic trioxide in HepG2 liver cancer cells. Cellular Signalling, 2025:111752.

        [2] Wu X*, Zhong Z L, Lin K M, Liu X H, Wu Z C, Liu Z T, Li Y M*. Comparative pharmacokinetics and urinary excretion of arsenic and mercury after oral administration of realgar, cinnabar and AnGongNiuHuang Pill to rats. Frontiers in Pharmacology, 2022, 13: 967608.

        [3] Wu X, Guan R, Liu Y X, Wu S H, Song M*, Hang T J*. Comparative health risk assessment of realgar and NiuHuangJieDu tablets based on tissue arsenic levels after multiple oral administration to rats. Journal of Ethnopharmacology, 2020, 249: 112370.

        [4] Wu X, Wu S H, Liu Y X, Guan R, Liang F M, Song M*, Hang T J*. Health risk assessment of arsenic in Realgar and NiuHuangJieDu Tablets based on pharmacokinetic study. Journal of Trace Elements in Medicine and Biology, 2018, 48: 81-86.

        [5] Wu X, Zeng X F, Wang L, Hang T J, Song M*. Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimization. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143: 17-25.